Live Support
Hypothetical Patient Profiles
The following hypothetical patient profiles have been developed as a way to show the risk of febrile neutropenia in specific cancer types.
Select a patient below to view their profile in detail.
Breast Cancer
Non-Hodgkins Lymphoma
Neulasta® Helps Your Eligible Patients with Co-pays
Enroll your practice in the Neulasta FIRST STEP® Co-pay Coupon Program now.
Evelyn
- Age: 43
- Weight: 190
- Height: 5’6”
Lab test results
- HER2-negative by FISH
- SLN Bx: 2 LNs negative
- ER-positive by IHC
- PR-positive
- 41 Oncotype DX® recurrence score
- SPF: -20%; Ki 67=30%; DNA content aneuploid
- Preoperative tests for lumpectomy were normal
Patient chemotherapy concerns
- Seeking a second opinion regarding her diagnosis with early-stage breast cancer
- Cost of child care during chemotherapy treatments
- High insurance co-payments and yearly deductible
Depending on the chemotherapy regimen, a patient like Evelyn may be at moderate or greater risk of febrile neutropenia.*
*Regimens associated with ≥17% risk of febrile neutropenia.
Mary
- Age: 70
- Weight: 185
- Height: 5’4”
Lab test results
- HER2-negative by FISH
- SLN Bx: 1 LN positive
- ER-positive by IHC
- PR-negative
- Lymphovascular invasion: present
- SPF: -20%; Ki 67=30%; DNA content aneuploid
- LVEF: 51%
- Preoperative tests for lumpectomy were normal with the exception of elevated serum glucose levels
Patient chemotherapy concerns
- Has trouble managing her diabetes mellitus
- Has difficulty walking due to COPD
- Seeking a second opinion regarding her diagnosis with intermediate- to high-grade infiltrating ductal carcinoma
Depending on the chemotherapy regimen, a patient like Mary may be at moderate or greater risk of febrile neutropenia.*
*Regimens associated with ≥17% risk of febrile neutropenia.
Jackie
- Age: 47
- Weight: 130
- Height: 5’9”
Lab test results
- HER2-negative by FISH
- Nodal status: negative
- ER-positive
- PR-positive
- 40 Oncotype DX® recurrence score
Sara
- Age: 47
- Weight: 130
- Height: 5’5”
Lab test results
- HER2-negative by FISH
- Nodal status: negative
- ER-positive
- PR-positive
- 39 Oncotype DX® recurrence score
Patients, like Jackie and Sara, who have similar lab results, may be at moderate or greater risk of febrile neutropenia.*
*Regimens associated with ≥17% risk of febrile neutropenia.
Anthony
- Age: 50
- Weight: 195
- Height: 5’11”
Lab test results
- WBC count: 4.1 x 109/L
- Hgb: 11.2 g/dL
- Platelet count:
153 x 109/L - Bilirubin: 2.0 mg/dL
- Albumin: 2.2 g/dL
- Hepatitis B and C and HIV are negative
- Bone marrow aspirate is negative
Patient chemotherapy concerns
- Manages his diabetes mellitus with insulin
- Has smoked heavily for 30+ years and has impaired pulmonary function
- Seeking a second opinion regarding his diagnosis with diffuse large B-cell lymphoma
Depending on the chemotherapy regimen, a patient like Anthony may be at moderate or greater risk of febrile neutropenia.*
*Regimens associated with ≥17% risk of febrile neutropenia.
Betty
- Age: 71
- Weight: 135
- Height: 5’6”
Lab test results
- WBC count: 6.5 x 109/L
- Hgb: 12.5 g/dL
- Platelet count:
200 x 109/L
- Bilirubin: 0.8 mg/dL
- Albumin: 3.6 g/dL
- LVEF: normal
Patient chemotherapy concerns
- Breast cancer 17 years ago, treated with modified radical mastectomy and CMF
- Hypertension controlled with medication
- Seeking a second opinion regarding her diagnosis with diffuse large B-cell lymphoma
Depending on the chemotherapy regimen, a patient like Betty may be at moderate or greater risk of febrile neutropenia.*
*Regimens associated with ≥17% risk of febrile neutropenia.
Indication
Neulasta® (pegfilgrastim) is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.
Neulasta is not indicated for the mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation.
Important Safety Information
Do not administer Neulasta to patients with a history of serious allergic reactions to pegfilgrastim or Filgrastim.
Splenic rupture, including fatal cases, can occur following the administration of Neulasta. Evaluate for an enlarged spleen or splenic rupture in patients who report left upper abdominal or shoulder pain after receiving Neulasta.
Acute respiratory distress syndrome (ARDS) can occur in patients receiving Neulasta. Evaluate patients who develop fever and lung infiltrates or respiratory distress after receiving Neulasta for ARDS. Discontinue Neulasta in patients with ARDS.
Serious allergic reactions, including anaphylaxis, can occur in patients receiving Neulasta. The majority of reported events occurred upon initial exposure. Allergic reactions, including anaphylaxis, can recur within days after the discontinuation of initial anti-allergic treatment. Permanently discontinue Neulasta in patients with serious allergic reactions.
Severe sickle cell crises can occur in patients with sickle cell disorders receiving Neulasta. Severe and sometimes fatal sickle cell crises can occur in patients with sickle cell disorders receiving Filgrastim, the parent compound of pegfilgrastim.
The granulocyte colony-stimulating factor (G-CSF) receptor, through which pegfilgrastim and Filgrastim act, has been found on tumor cell lines. The possibility that pegfilgrastim acts as a growth factor for any tumor type, including myeloid malignancies and myelodysplasia, diseases for which pegfilgrastim is not approved, cannot be excluded.
Bone pain and pain in extremity occurred at a higher incidence in Neulasta-treated patients as compared with placebo-treated patients.
© 2011 Amgen Inc. All rights reserved. MC49791-B
